The AI Biotech Fund is a specialised, data-driven investment fund combining artificial intelligence and fundamental analysis to uncover mispriced opportunities in the biotech sector. We focus on companies approaching key clinical trial catalysts — where rigorous analysis and predictive modelling can create asymmetric outcomes.
Our proprietary AI model incorporates Opyl’s TrialKey platform — an engine trained on over 450,000 historical clinical trials to estimate the probability of success — and integrates traditional company and macro fundamentals to identify high-probability, high-impact events. These insights are complemented by deep fundamental research into mechanism of action, competitive landscape, and risk-reward profile, enabling conviction-weighted investment decisions.
Designed for wholesale investors, the fund offers a disciplined strategy grounded in predictive analytics, active portfolio management, and rigorous due diligence — transforming complexity into opportunity.
Company Details
- Employees
- 3
- Address
- Is What We’re Built For. At The Ai Biotech Fund
- Industry
- Investment Management
- NAICS
-
Other Financial Investment ActivitiesPortfolio ManagementAll Other Financial Investment ActivitiesTrust, Fiduciary, and Custody ActivitiesMiscellaneous Financial Investment Activities
- Website
- https://aibiotechfund.com/
- Keywords
- St Kilda.
Ai Biotech Fund Questions
Ai Biotech Fund's website is https://aibiotechfund.com/
Ai Biotech Fund's LinkedIn profile is https://www.linkedin.com/company/ai-biotech-fund
Ai Biotech Fund has
3 employees.
View email and phone details for 3
employees at Ai Biotech Fund.
Ai Biotech Fund's industry is
Investment Management
Ai Biotech Fund's top competitors are
Universal Business Services Pty Ltd,
Canary Regulatory Affairs,
Ai In Biotech,
Opyl,
Trialkey,
Advantage Data Consulting,
D23 Capital & Advisory,
Spotter Finance,
Commercial Eyes Pty Ltd,
L39 Capital.
Ai Biotech Fund's categories are Investment Management
